Paragon Genomics

Executive Summary

Paragon Genomics, founded in 2015 and based in Fremont, California, is a biotechnology company specializing in innovative next-generation sequencing (NGS) library preparation solutions. The company's technology enables high-quality, multiplexed sequencing from challenging, low-input samples, addressing critical needs in genomics research and clinical diagnostics. By improving the efficiency and accuracy of NGS workflows, Paragon Genomics empowers researchers and clinicians to obtain reliable results from limited biological material, such as liquid biopsies or formalin-fixed paraffin-embedded (FFPE) tissues. Their platform is particularly valuable in applications like oncology, rare disease detection, and infectious disease monitoring, where sample quality and quantity are often limiting factors. The company operates in the rapidly growing NGS market, driven by increasing adoption of precision medicine and non-invasive diagnostics. Paragon Genomics differentiates itself through proprietary chemistry and streamlined protocols that reduce complex library preparation steps and minimize bias. While the company is privately held and does not disclose financials, its technology has garnered attention from academic and commercial laboratories. Key growth drivers include expansion of clinical applications, partnerships with diagnostic developers, and penetration into emerging markets. With a capital-efficient model and a focus on high-impact challenges, Paragon Genomics is positioned to benefit from the ongoing shift toward routine genomic testing in healthcare.

Upcoming Catalysts (preview)

• Q4 2026Launch of enhanced library prep kit for liquid biopsy70% success
• H1 2027Strategic partnership with major diagnostics company for NGS cancer panels60% success
• Q3 2026Closing of Series B funding round80% success